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Abstract
Background: Low blood pressure (BP) is associated with frailty in older adults. Our aim
was to explore how BP predicts transitions between frailty states.
Methods: We used data from the Lausanne cohort Lc65þ, a population-based cohort of
older adults randomly drawn from a population registry in Switzerland, in 2004, 2009
and 2014. BP was measured using a clinically validated oscillometric automated device
and frailty was defined using Fried’s phenotype, every 3 years. We used an illness-death
discrete multi-state Markov model to estimate hazard ratios of forward and backward
transitions between frailty states (outcome) in relation to BP categories (predictor of in-
terest) with adjustment for sex, age and antihypertensive medication (other predictors).
Results: Among 4200 participants aged 65–70 years (58% female) at baseline, 70% were
non-frail, 27% pre-frail and 2.0% frail. Over an average follow-up of 5.8 years, 2422 transi-
tions were observed, with 1575 (65%) forward and 847 (35%) backward. Compared with
systolic BP (SBP) <130 mmHg, the hazard ratio (95% confidence interval) of the transition
from non-frail to pre-frail was 0.86 (0.74 to 1.00) for SBP 130–150 mmHg, and 0.89 (0.74 to
1.06) for SBP 150 mmHg. Compared with SBP <130 mmHg, the hazard ratio of the tran-
sition from pre-frail to frail was 0.71 (0.50 to 1.01) for SBP 130–150 mmHg, and 0.90 (0.62
to 1.32) for SBP 150 mmHg. Diastolic BP was a weaker predictor of forward transitions.
Conclusions: BP categories had no strong relationship with either forward transitions or
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backward transitions in frailty states. If our findings are confirmed with greater precision
and assuming a causal relationship, they would suggest that there is no well-defined op-
timal BP level to prevent frailty among older adults.
Key words: Blood pressure, frailty, ageing, cohort studies, epidemiology
Introduction
Several cross-sectional studies have shown that low blood
pressure (BP) is associated with frailty in older adults.1,2
Frailty is a geriatric syndrome of vulnerability and loss of
adaptability to stress, predicting an increased risk of ad-
verse health outcomes such as falls, hospitalization and
premature death.3 For instance, in the population-based
Lausanne cohort Lc65þ including older adults aged
65 years and more, pre-frail individuals had on average a
lower systolic blood pressure (SBP) by 2.7 mmHg and frail
individuals by 6.7 mmHg, compared with non-frail
individuals.1
These findings contribute to the current uncertainties
surrounding hypertension management in older adults.
Indeed, it is still debated whether intense hypertension
management in older adults is beneficial, especially in
those who are vulnerable and frail.4 This translates into
discordant recommendations from major international hy-
pertension management guidelines.5 For instance, the 2017
American College of Cardiology/American Heart
Association (ACC/AHA) Guidelines recommended inten-
sive hypertension management with BP targets below 130/
80 mmHg,6 whereas the 2017 Guidelines by the American
College of Physicians and the American Academy of
Family Physicians (ACP/AAFP) recommended a more con-
servative treatment with BP targets below 150/90 mmHg.7
Investigating how these BP levels predict frailty may help
in identifying older adults at risk for the development of
frailty according to their BP level. Further, if BP predicts
frailty, this could indicate a causal relationship, hence cer-
tain BP levels might be detrimental by causing frailty in
older adults.
Currently, few studies have investigated the longitudi-
nal relationship between BP and frailty. In these studies,
BP did not predict or only weakly predicted incident frailty
over time2; the dynamic nature of frailty, i.e. the fact that
individuals can move back and forth through frailty states,
was however not accounted for. In 2019, the Lancet pub-
lished a two-paper series in which the authors called for
appropriate statistical methods to capture and account for
the dynamics of frailty over time.3,8 One suitable method
to describe the progression of a dynamic condition is
multi-state modelling.9 Multi-state models describe how
individuals move through different stages of a disease or a
condition.9 Applied to frailty, multi-state models allow
researchers to: (i) incorporate the fact that individuals
move between frailty states over time, i.e. non-frail, pre-
frail and frail; and (ii) assess how variables such as BP pre-
dict transitions between frailty states while accounting for
the competing risk of death. Multi-state models may help
to better characterize the relationship between BP and the
dynamic of frailty.
In this study, our aim was to explore how BP predicts
transitions between frailty states over time using a multi-
state model applied to data from a cohort study of older
adults. We hypothesized that compared with intermediate
BP, low BP would predict more forward transitions in
frailty states, i.e. worsening health. The current study is, to
Key Messages
• Low blood pressure (BP) is associated with frailty in older adults in cross-sectional studies.
• Frailty is a dynamic condition: individuals transition forwards and backwards through several states of progressive
severity in frailty.
• An illness-death model allowed us to explore transition rates between three frailty states, i.e. non-frail, pre-frail and
frail, and to assess how BP predicts transitions in frailty.
• We found that BP categories had no strong relationship with either forward transitions or backward transitions in
frailty states.
• Our findings might suggest that there is no well-defined optimal BP level to prevent frailty among older adults.
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our knowledge, the first to investigate how BP predicts
transitions between frailty states, capturing the dynamic
nature of both BP and frailty.
Methods
The Lc65þ study was approved by the Ethics Committee
of the Faculty of Biology and Medicine of the University of
Lausanne, Switzerland.
Study population
We used data from the Lausanne cohort Lc65þ.10,11 The
cohort was originally designed to investigate frailty and its
determinants and evolution over time. Initially, three rep-
resentative samples of older adults aged 65 to 70 years re-
siding in the city of Lausanne, Switzerland, were invited by
mail to participate in 2004, 2009 and 2014
(Supplementary Figure S1, available as Supplementary
data at IJE online). These samples were drawn at random
from the population registry of the city of Lausanne.
Individuals living in institutions or not able to respond by
themselves to questionnaires due to advanced dementia
were excluded. Data were collected through questionnaires
every year and through physical and cognitive measure-
ments every 3 years. The physical and cognitive measure-
ments started in 2005 in Lc65þ sample one, 2010 in
sample two and 2015 in sample three, and these time
points were considered as baseline for the present analyses
(Supplementary Figure S2, available as Supplementary
data at IJE online).
For the statistical analyses, we used data from the three
samples up to 2018, i.e. for Lc65þ sample one we used
frailty and BP measurements collected in 2005, 2008,
2011, 2014 and 2017; for Lc65þ sample two, we used
frailty and BP measurements collected in 2010, 2013 and
2016; and for Lc65þ sample three, we used frailty and BP
measurements collected in 2015 and 2018. Data collection
was done over the whole year, e.g. in sample three data
were collected from 13 February 2015 to 14 December
2015 at baseline, and from 8 February 2018 to 11
December 2018 at 3 years’ follow-up. We excluded indi-
viduals who died or left the study between recruitment and
baseline and those who had fewer than two measurements
of frailty over the whole observation period and therefore
had no observed transition among the frailty states
(Supplementary Figure S1).
Measurement of frailty and blood pressure
Frailty was defined using Fried’s phenotype.12 Fried’s phe-
notype is based on five criteria: weakness, slowness, weight
loss, exhaustion and low physical activity. The way these
criteria were measured in the Lc65þ study is described in
detail elsewhere.1,10,13 Briefly, weakness and slowness
were measured through physical measurements of, respec-
tively, grip strength with a dynamometer and gait speed
with a walking test. In some cases when the walking test
and the grip strength test could not be performed, slowness
and weakness were imputed based on the judgment of the
research assistant following pre-established decision algo-
rithms1; the decision algorithms are described in
Supplementary Boxes S1 and S2, available as
Supplementary data at IJE online. Weight loss, exhaustion
and low physical activity were assessed by self-report. The
assessment of frailty was done following a standardized
procedure identically applied across follow-ups in the three
samples. Three frailty states were defined: (i) non-frail if
participants had no criteria fulfilled; (ii) pre-frail if they
met one or two criteria; and (iii) frail if they met three or
more criteria.
BP was measured at the study centre by trained medical
research assistants using a clinically validated oscillometric
automated device and following a standardized protocol
across years. The detailed procedure is described else-
where.1,10,13 Briefly, BP was measured after 10 to 20 min
of rest in a sitting position, with a cuff size adapted to the
participant’s arm circumference, three times at 5–10-min
intervals at each follow-up visit. The mean of the three BP
measurements was used for our analyses.
We defined BP categories to reflect BP targets in older
adults as suggested by two conflicting international hyper-
tension management guidelines: the 2017 ACC/AHA
Guideline and the 2017 Guideline by the ACP/AAFP.10,11
For the primary prevention of cardiovascular disease in
community-dwelling older adults, the ACC/AHA 2017 rec-
ommended targeting BP below 130/80 mmHg, whereas the
ACP/AAFP 2017 recommended targeting below 150/
90 mmHg. Hence, we defined three categories of SBP and
diastolic BP (DBP): SBP <130 mmHg, 130 SBP
<150 mmHg, and SBP 150 mmHg; and DBP
<80 mmHg, 80DBP <90 mmHg, and DBP 90 mmHg,
respectively.
Measurement and definition of other variables
Date of birth and sex were taken from the residential regis-
try and date of death was obtained through linkage with
death certificates obtained through the canton of Vaud
population registry.10 Antihypertensive medication use
was defined for participants, who answered ‘yes’ to the
question: ‘Are you currently taking medication at least
once a week to lower your blood pressure (hypertension)?’.
At baseline, information on self-reported hypertension,
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other cardiovascular risk factors [hypercholesterolaemia,
diabetes, history of cardiovascular disease, smoking status,
body mass index (BMI) category], number of chronic con-
ditions, polypharmacy and level of education were col-
lected. Hypertension was defined for participants who
reported a diagnosis or use of BP-lowering medication;
hypercholesterolaemia as diagnosis or use of cholesterol-
lowering medication; diabetes as diagnosis or use of insu-
lin; history of cardiovascular disease as diagnoses of
stroke, coronary artery disease or another heart disease or
use of medication for the heart; and smoking as current
smoking (former- and never-smokers were defined as non-
smokers). BMI was defined based on measured weight and
height. BMI categories were underweight (BMI <18.5 kg/
m2), normal weight (BMI 18.5–24.9 kg/m2), overweight
(BMI 25.0–29.9 kg/m2) and obesity (BMI 30.0 kg/m2).
The number of chronic conditions was the sum of the fol-
lowing self-reported conditions: hypertension, hypercho-
lesterolaemia, coronary heart disease, stroke, diabetes,
chronic pulmonary disease, osteoporosis, arthrosis,
Parkinson’s disease and obesity. Participants had polyphar-
macy if they answered five or more to the question: ‘How
many different brand name medications do you regularly
take at this time?’.14
State definition and transitions
We defined four states that included three frailty states, i.e.
non-frail, pre-frail and frail, and an absorbing state of
death (Figure 1). The state of death is called absorbing be-
cause once a participant enters the state, he or she remains
in that state. In comparison, the frailty states are not
absorbing but transient states, because when a participant
is in one of the frailty states, he or she can still move to
other states.9 These states were observed every 3 years and
thus were interval censored, i.e. participants were in un-
known states between observation times. In Lc65þ sample
one, the states were observed at baseline and at 3-, 6-, 9-
and 12-year follow-up, that is five observation times with
four 3-year intervals in between. In Lc65þ sample two, the
states were observed at baseline and at 3- and 6-year fol-
low-up, that is three observation times with two 3-year
intervals in between. In Lc65þ sample three, the states
were observed at baseline and at 3-year follow-up, that is
two observation times with one 3-year interval in between.
An interval was defined by two successive visits with
physical measurements, e.g. during the time between base-
line and 3-year follow-up. At the beginning of an interval,
participants can be in either of the three frailty states. They
can stay in the same state, experience a forward or a back-
ward transition to any consecutive frailty state, or die
(Figure 1). Transitions were defined when a participant
moved from one frailty state to another over time.
Transitions could be forwards, i.e. from non-frail to pre-
frail or from pre-frail to frail, or backwards, i.e. from frail
to pre-frail or from pre-frail to non-frail. Transitions were
not observed per se, they occurred during an interval.
Statistical analyses
We computed means and standard deviations (SD) for nor-
mally distributed continuous variables, median [minimum
to maximum (min–max)] for non-normally distributed
continuous variables and counts (percentages) for
Figure 1 Multi-state transition model; in rectangles are the states, with three frailty states and an absorbing state of death The arrows indicate permit-
ted transitions. Over time, individuals move forward or backward in frailty states, remain in the same frailty state or die
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categorical variables. We calculated the observed propor-
tions of participants who were alive, dead or dropped out
at baseline and at 3-, 6-, 9- and 12-year follow-up. Further,
among those alive, we calculated the proportion of non-
frail, pre-frail and frail at baseline and at 3-, 6-, 9- and 12-
year follow-up. To count the number of consecutive pairs
of states, including forward and backward transitions in
frailty as well as transitions to death and censored states,
we used the state.msm function from the msm package in
R. Participants’ states were censored if they withdrew from
the study, were excluded or lost to follow-up. To visualize
transitions between frailty states and death for each of the
Lc65þ samples separately, we built flow diagrams (Sankey
plot) using the networkD3 package in R. We calculated the
total mean person-years (SD; min–max) by adding each
participant’s time from baseline to death, or censoring.
To model transitions in frailty states over time, we used
a discrete multi-state Markov model, applying the msm
package in R.9 The resulting output of the multi-state
model is a matrix of instantaneous transition rates between
states with hazard ratios for BP categories and other cova-
riates. The underlying Markov assumption is that future
transitions in frailty only depend on the current state; the
model is memoryless and is not influenced by the history of
state transitions prior to the current state. Censored indi-
viduals, i.e. excluded or lost to follow-up, were accounted
for. One additional assumption is that participants cannot
skip a state in the process. It is however possible, e.g. that
participants non-frail at the beginning of an interval were
directly frail at the end. In these cases, the model implicitly
considered that these participants transited through pre-
frailty during the interval, even if it had not been recorded.
To investigate the predictive effect of BP (predictor of
interest) on transition rates in frailty (outcome), we built
several multi-state Markov models9 with the transition
rates regressed on BP category, first unadjusted (model 0)
and second adjusted for sex, age category (age <75 years
vs age 75 years) and antihypertensive medication use at
baseline (other predictors; model 1). We built separate
models for SBP and DBP categories. Age and BP categories
were integrated as time-varying covariates, which means
that transitions over an interval, e.g. from baseline to 3-
year follow-up, were regressed on the age and BP catego-
ries measured at baseline, with both assumed to stay con-
stant over the interval.9
We verified the assumption of constant transition rates
through visual checking, comparing observed against pre-
dicted proportions of frailty states and death over time.5
Where the assumption held, i.e. the proportions of ob-
served and predicted states remained similar over time, we
would keep the time-homogeneous model, i.e. with con-
stant transition rates over the observation period. Where
the assumption did not hold i.e. there were large discrepan-
cies between the proportion of observed and predicted
states over time, we would create a time-non-homogeneous
model, i.e. with piecewise constant transition rates over
the observation period (model 2).
To assess potential selection bias, we compared baseline
characteristics of participants in the analytical sample with
participants excluded because they had fewer than two
measurements of frailty over the observation period
(Supplementary Table S1, available as Supplementary data
at IJE online). To address missing data, we computed the
proportion of missing data in frailty assessments at each
data collection time point and summarized them in
Supplementary Table S2, available as Supplementary data
at IJE online. For baseline characteristics, missing data in
self-reported hypertension diagnosis, antihypertensive
medication intake, variables defining other cardiovascular
risk factors, variables defining the number of chronic con-
ditions and the variable defining polypharmacy were inter-
preted as absence of those characteristics. For the analyses,
other missing data were left as they were. In the multi-state
transition models, missing observations were censored.9
Results
Out of 15 175 residents of the city of Lausanne,
Switzerland, aged 65 to 70 years, 9887 were invited to par-
ticipate in the Lc65þ cohort study and 4731 (48% of in-
vited) agreed to participate. In all 459 (10%) individuals
were excluded from the analytical sample as they died or
were lost to follow-up, and 72 (1.5%) individuals were ex-
cluded because they had fewer than two measurements of
frailty over the observation period. Some 4200 participants
(58% females) were included in the present analyses
(Supplementary Figure S1). At baseline, the median (min–
max) age was 69 (66–71) years. The mean BP [SBD (SD)/
DBP(SD)] was 137(19)/79(11) mmHg and 37% of partici-
pants reported taking antihypertensive medication
(Table 1). At baseline, the proportions of non-frail, pre-
frail and frail were 70%, 27% and 2.0%, respectively. At
3-, 6-, 9- and 12-year follow-up, the proportions of indi-
viduals with frailty were 2.8%, 3.7%, 4.4% and 8.4%, re-
spectively (Supplementary Table S2). The proportion of
individuals for whom frailty was assessed using the pre-
established imputation algorithm was below 5% at base-
line and reached about 10% among the participants who
were followed-up for the longest period of time, i.e.
12 years (data not shown). The participants who were ex-
cluded because they had fewer than two measurements of
frailty were slightly less educated and were overall slightly
less healthy than individuals in the analytical sample
(Supplementary Table S1).
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Over 24 483 person-years of follow-up, with a mean
(SD; min–max) follow-up per participant of 5.8 (5.2; 3–
12) years, we observed 2422 transitions. Of those, 1575
(65%) were forward transitions—1336 (55%) transitions
from non-frail to pre-frail and 179 (7.4%) from pre-frail to
frail states—and 847 (35%) were backward transitions—
82 (3.4%) transitions from frail to pre-frail and 755 (31%)
from pre-frail to non-frail states (Table 2). Supplementary
Table S3, available as Supplementary data at IJE online,
shows all observed pairs of consecutive states (frailty
states, death), including those who moved to a censored
state. Among non-frail, pre-frail and frail individuals, 118,
172 and 36 transitions to death were observed, respec-
tively. These transitions represented 2.1%, 6.7% and 17%
of all transitions among those who were, respectively, non-
frail, pre-frail and frail at the beginning of the interval.
Among non-frail, pre-frail and frail individuals, 284, 160
and 20 participants, respectively, moved to a censored
state. These transitions represent 5.1%, 6.3% and 9.3% of
all transitions among those who were, respectively, non-
frail, pre-frail and frail at the beginning of the interval.
Figure 2 shows a flow diagram of state transitions in sam-
ple one of the Lc65þ cohort and Supplementary Figure S3,
available as Supplementary data at IJE online shows flow
diagrams in samples two and three.
Through visual checking,9 we compared observed and
predicted proportions of frailty states and death over time
for the adjusted time-homogeneous multi-state model
(model 1) and concluded that the assumption of constant
transitions rates did not hold (Supplementary Figure S4,
available as Supplementary data at IJE online). This mod-
el’s predictions overestimated the proportion of frailty
states at the expense of underestimating the proportion of
death at 12-year follow-up. Hence, we based our final esti-
mates on a time-non-homogeneous model with piecewise
constant transition rates for the periods from baseline to
9 years, and from 9 to 12 years (model 3). Table 3 summa-
rizes hazard ratios of forward transitions in frailty states
by SBP (panel A) and DBP (panel B) for model 0, model 1
and model 2.
In the time-non-homogeneous model, adjusted for sex,
age category and antihypertensive medication use (model
2), compared with SBP <130 mmHg, the hazard ratio
Table 1 Baseline characteristics of participants
Characteristics N (%)
Total N 4200 (100%)
Sex Women 2442 (58%)
Men 1758 (42%)
Age (years), median (min–max) 69 (66–71)




Sysolic BP [mmHg], mean (SD) 137 (19)
Sysolic BP category SBP <130 1378 (33%)
130  SBP <150 1531 (36%)
SBP 150 926 (22%)
Diastolic BP [mmHg], mean (SD) 79 (11)
Diastolic BP category DBP <80 2055 (49%)
80 DBP <90 1140 (27%)
DBP 90 640 (15%)
Missing in BP 365 (8.7%)
Hypertension 1755 (42%)
Hypertension treatment 1568 (37%)
Other cardiovascular risk factors
Hypercholesterolaemia 1592 (38%)
Diabetes 409 (9.7%)
History of cardiovascular disease 779 (19%)
Smoking status 769 (18%)
BMI category Underweight 56 (1.3%)








Education Basic compulsory 811 (19%)
Apprenticeship 1642 (39%)
High school 1008 (24%)
University 730 (17%)
Missing 9 (0.2%)
Values are numbers (%) unless indicated otherwise. N, number of partici-
pants; SD, standard deviation; BP, blood pressure; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; polypharmacy, five categories of
medications at least once a week.
Table 2 Number (%) of observed forward transitions and
backward transitions in frailty states over 24 483 person-
years of follow-up, i.e. a mean (SD) follow-up per participant
of 5.8 (5.2) years
Transitions N (%)
Forward 1575 (65%)
Non-frail to pre-frail 1336 (55%)
Non-frail to frail 60 (2.5%)
Pre-frail to frail 179 (7.4%)
Backward 847 (35%)
Pre-frail to non-frail 755 (31%)
Frail to pre-frail 82 (3.4%)
Frail to non-frail 10 (0.4%)
Forward and backward 2422 (100%)
Percentage was computed in relation to the total number of forward and
backward transitions, respectively.
N ¼ number of transitions.
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[95% confidence interval (CI)] of the transition from non-
frail to pre-frail was 0.86 (0.74 to 1.00) for SBP 130–
150 mmHg and 0.89 (0.74 to 1.06) for SBP  150 mmHg.
Compared with SBP <130 mmHg, the hazard ratio of the
transition from pre-frail to frail was 0.71 (0.50 to 1.01) for
SBP 130–150 mmHg and 0.90 (0.62 to 1.32) for SBP
150 mmHg.
Further, compared with DBP <80 mmHg, the hazard
ratio of the transition from non-frail to pre-frail was 0.90
(0.77 to 1.04) for DBP 80–90 mmHg and 0.93 (0.76 to
1.13) for DBP 90 mmHg. Compared with DBP
<80 mmHg, the hazard ratio of the transition from pre-
frail to frail was 1.01 (0.70 to 1.44) for DBP 80–90 mmHg
and 1.03 (0.65 to 1.63) for DBP 90 mmHg (Table 3).
Hazard ratios of backward transitions (frail to pre-frail
and pre-frail to non-frail) by BP categories can be found in
Supplementary Table S4, available as Supplementary data
at IJE online.
Discussion
Our study showed that among transitions in frailty states,
about two-thirds were forward and one-third was
backward. We found that BP categories had no strong rela-
tionship with either forward transitions or backward tran-
sitions in frailty states. Our findings are, however, subject
to uncertainty as revealed by the wide confidence intervals
around point estimates.
Several studies, cross-sectional or longitudinal, have
been conducted on the relationship between BP and frailty.
Longitudinal studies investigated how BP predicts frailty
over time using time-to-event analysis, which only captures
forward transitions or analyses of association using odds
ratios or risk ratios.2 In a study by Bouillon et al., hyper-
tension (BP 130/85 mmHg or antihypertensive medica-
tion use) predicted an increased probability of being frail
or pre-frail at 10 years [unadjusted odds ratio (OR), 95%
CI: 1.25, 1.06 to 1.46].15 In a time-to-event analysis by
Barzilay et al., increased BP (130/85 mmHg) at baseline
predicted the incidence of frailty in univariate analyses
[hazard ratio (HR), 95% CI: 1.16, 1.01 to 1.33].16 Therein
the associations became weaker when adjusted for other
cardio-metabolic and health-related variables. These stud-
ies were, however, not designed to specifically characterize
how BP predicts frailty. The study by Bouillon et al. failed
to disentangle the effect of antihypertensive medication
Figure 2 Transitions in frailty states in sample one of the Lc65þ cohort. Baseline 3 years (yrs) of follow-up (f-u), 6 yrs f-u, 9 yrs f-u, 12 yrs f-u. Numbers
are participant counts in each frailty state (%), i.e. non-frail (nf), pre-frail (pf) and frail (f)
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and BP. Further, since frailty is a dynamic condition with
frequent forward and backward transitions, a time-to-
event approach may not be appropriate.
The current study is, to our knowledge, the first to in-
vestigate how BP predicts—prospectively—transitions be-
tween frailty states, capturing the dynamic nature of both
BP and frailty. The main strength of our study is the use of
multi-state modelling to assess the predictive value of BP
on transitions in frailty, based on observed states. BP was
integrated as a time-varying covariate, which allowed ac-
counting for changes in BP over time notably for a poten-
tial end-of-life BP decline,17,18 and transition rates were
modelled in a piecewise constant manner, taking into ac-
count strong increase in death rates with advancing age.
Additional strengths of our study are its population-
based sampling, the long follow-up, and the accuracy of
the data.10 Specifically, the components of frailty and BP
were collected over time following a standardized protocol
kept identical across years. Furthermore, data collection in
the Lc65þ was done at fixed intervals specified in advance.
That kind of observation scheme, compared with patient
self-selection, avoids bias in the estimation of transition
rates because data were collected independently of disease
progression.9,19 In contrast, in observational schemes rely-
ing on patient self-selection, e.g. data collected at the hos-
pital during routine clinical practice, individuals
experiencing disease progression may be over-represented
compared with those who stay healthy over time, thus
leading to an overestimation of forward transition rates.19
One limitation of our study is the Markov assumption
underlying the multi-state models. The Markov assump-
tion implies that future transitions in frailty only depend
on the current state.9 This may not necessarily be the case,
but as we plotted the observed against the estimated pro-
portion of states, we saw that the model fits the data rea-
sonably well (Supplementary Figure S4, available as
Supplementary data at IJE online). Further, although our
method requires that some participants transit from non-
frail to frail or the opposite in a single transition, our
model assumes that individuals can only transit between
consecutive states. This may be wrong, but since frailty is
considered a progressive syndrome of continuously
Table 3 Hazard ratios (95% confidence interval) of forward transitions in frailty states by systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) category. Panel A are transitions by SBP category and panel B by DBP category
A
Model State transition SBP <130 130  SBP <150 SBP 150 Women Antihypertensive
medication
Model 0 Non-frail to pre-
frail
1 0.91 (0.78 to 1.05) 0.96 (0.81 to 1.14) –
Pre-frail to frail 1 0.65 (0.45 to 0.95) 1.06 (0.67 to 1.65) –
Model 1 Non-frail to pre-
frail
1 0.90 (0.78 to 1.03) 0.96 (0.81 to 1.14) 1.10 (0.97 to 1.24)
Pre-frail to frail 1 0.66 (0.46 to 0.95) 1.00 (0.67 to 1.48) 1.12 (0.79 to 1.58)
Model 2 Non-frail to pre-
frail
1 0.86 (0.74 to 1.00) 0.89 (0.74 to 1.06) 1.17 (1.03 to 1.33) 1.30 (1.14 to 1.48)
Pre-frail to frail 1 0.71 (0.50 to 1.01) 0.90 (0.62 to 1.32) 1.18 (0.85 to 1.64) 1.63 (1.21 to 2.21)
B
Model State transition DBP <80 80 DBP <90 DBP 90 Women Antihypertensive
medication
Model 0 Non-frail to pre-
frail
1 0.87 (0.75 to 1.00) 0.92 (0.70 to 1.19) –
Pre-frail to frail 1 0.91 (0.61 to 1.37) 1.13 (0.64 to 2.01) –
Model 1 Non-frail to pre-
frail
1 0.90 (0.78 to 1.04) 0.96 (0.79 to 1.15) 1.11 (0.98 to 1.25)
Pre-frail to frail 1 1.09 (0.76 to 1.56) 1.17 (0.73 to 1.89) 1.22 (0.87 to 1.71)
Model 2 Non-frail to pre-
frail
1 0.90 (0.77 to 1.04) 0.93 (0.76 to 1.13) 1.18 (1.04 to 1.35) 1.28 (1.12 to 1.46)
Pre-frail to frail 1 1.01 (0.70 to 1.44) 1.03 (0.65 to 1.63) 1.22 (0.87 to 1.70) 1.62 (1.20 to 2.18)
Blood pressure category was accounted for as a time-varying covariate and blood pressure values are in mmHg. Model 0: unadjusted; model 1: adjusted for sex
and age category (age <75 years; age 75 years); model 2: time-non-homogeneous with piecewise constant transitions from baseline to 9 years and from 9 to
12 years, adjusted for sex, age category (age <75 years; age 75 years) and antihypertensive medication use at baseline.
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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depleting energy that develops with older age,12 this as-
sumption seems credible in the majority of the cases.
Another limitation is that frailty and BP were measured
only every 3 years and not on a continuous basis. Hence,
transitions were not observed per se; instead, they were
assessed based on observed states at the times of study
visits.
Another potential limitation in our study is related to the
known possibility of convergence failure in complex models.
To mitigate this possibility, we included a small number of
covariates in the multi-state transition models, and we catego-
rized both age and BP rather than including them as continu-
ous covariates. Adjusting for potential predictors of frailty
(e.g. income, unhealthy lifestyle, multimorbidity20) or poten-
tial confounders of the relationship between BP and frailty
(e.g. cardiovascular risk factors) would have allowed us to
better isolate the predictive effect of BP on frailty devoid of
the effect of other predictors and accounting for some con-
founding. Furthermore, including BP and age as continuous
covariates, e.g. using splines to model non-linear effects,
could have resulted in a more precise predictive model of BP
on frailty. Multi-state transition models are, however, limited
in the number and complexity of variables that can be in-
cluded simultaneously, as complex models often fail to reach
convergence.9 A further limitation is the use of self-reported
data for several baseline characteristics, notably chronic con-
ditions. The information about chronic conditions might
have been more accurate if collected from medical health
records.21
Other limitations of our study are the relatively low pro-
portion of frailty and the potential impact of selection bias.
The proportion of frailty was 2.0% among participants aged
67 to 71 years and 8.4% among participants aged 78–
83 years. In a systematic review including studies on
community-dwelling older adults aged 65 years and more in
high-income countries and using Fried’s phenotype to opera-
tionalize frailty, the pooled prevalence estimates ranged be-
tween 4% and 17%.22 Across age categories, the estimates
were 4.1% (95% CI: 3.4 to 4.8) in the 65–69 age group,
6.8% (95% CI: 5.7 to 7.9) in the 70–74, 9.9% (95% CI: 8.6
to 11.2) in the 75–79, 15.7% (95% CI: 13.5 to 17.9) in the
80–84 and 26.1% (95% CI: 22.1 to 30.1) in the 85years and
more group.22 These estimates are higher than ours. This dif-
ference might be due to some selection bias. First, 52% of
individuals invited to the study refused to participate. Second,
72 individuals were excluded from the analytical sample
(1.5% of the cohort) because they had fewer than two assess-
ments of frailty throughout the follow-up. Third, attrition in-
creased over time and reached 14% at 12-year follow-up.
Fourth, missing data were not imputed in this analysis.
Hence, taken together, our findings are subject to selection
bias through healthy participant, attrition and healthy
survivor biases. Nevertheless, the age and sex distributions of
the Lc65þ cohort samples were not different from the sam-
pled population.23,24 It is also possible that the prevalence of
frailty is relatively low in Switzerland; using data from the
Survey of Health, Aging and Retirement in Europe (SHARE),
Santos-Eggimann et al. reported a lower prevalence of frailty
in Switzerland compared with other European countries.25
Our findings raise the question as to what is the optimal
BP level in older adults. We found that BP categories had
no strong relationship with either forward transitions or
backward transitions in frailty states. Our findings are,
however, subject to large uncertainty as revealed by the
wide confidence intervals around point estimates. This sug-
gests that we have a relatively small sample to address our
research question. A larger sample would be needed to
confirm or refute our findings, e.g. the Canadian
Longitudinal Study on Aging (CLSA) that follows up 50
000 individuals aged between 45 and 85 years.26 Another
data source may be electronic health records and adminis-
trative claims data, although identifying frailty in such
data remains challenging.27 Increasing the sample size
would eventually allow the construction of more complex
models, including BP as a continuous variable instead of a
categorical one, with adjustment for several confounding
factors without convergence failure.
If our findings were to be confirmed with greater preci-
sion and assuming a causal relationship between BP and
frailty, they would suggest that there is no optimal BP to
prevent frailty among older adults.28 Further studies are
needed to investigate the causal relationship between BP
and frailty. These studies may eventually give some further
indication on how to account for frailty in the management
of hypertension in older adults.
To conclude, the current study is, to our knowledge, the
first to investigate how BP predicts transitions between
frailty states, capturing the dynamic nature of both BP and
frailty. The multi-state illness-death model allowed us to
investigate the relationship between BP and frailty in a dy-
namic system with multiple states, encompassing both for-
ward and backward transitions. We found that BP
categories did not strongly predict transitions in frailty
states. Due to the large uncertainty in our findings, further
studies are needed to confirm or not the absence of optimal
BP for the prevention of frailty.
The data can be acquired through the Lc65þ study
investigators. The computing codes are available upon re-
quest to the corresponding author.
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